Medical expert services to provide analysis of adverse event reports for the strategic development of compliance and enforcement targets in FDA-regulated commodities with CBD and THC for the FDA,…
Ended Awarded Last action
- Contract number
- 75F40123F19297
- Awardee
-
Brillient Corporation UEI MMAVC7UGLJ78
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $323,040
Award facts
- Contract value 100% obligated
- $323,040.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Competitive 8(a)
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$445 | |
| Original award | $323,485 |
About this award
The Food and Drug Administration issued a BPA call to Brillient Corporation under the GSA Multiple Award Schedule on August 23, 2023, with a ceiling value of $323,040.29. The call, set aside as Competitive 8(a), procures medical expert services to analyze adverse event reports and support strategic development of compliance and enforcement targets for FDA-regulated commodities containing CBD and THC, with place of performance in Reston, Virginia and ultimate completion August 26, 2024. Labor-hours pricing governs the engagement. In FY2024, the call generated $323 thousand in government-invoiced labor across 1,594 contractor hours (0.8 FTEs) at a blended rate of $202.66 per hour, with one subcontractor performing approximately 75 percent of reported hours.
Description
Medical expert services to provide analysis of adverse event reports for the strategic development of compliance and enforcement targets in FDA-regulated commodities with CBD and THC for the FDA, cfsan
Quick answers
Who was awarded contract 75F40123F19297?
75F40123F19297 was awarded to Brillient Corporation by Food and Drug Administration (Department of Health and Human Services) on August 23, 2023.
How much is contract 75F40123F19297 worth?
The government has obligated $323,040 on 75F40123F19297.
Is contract 75F40123F19297 an order under another contract?
Yes. 75F40123F19297 is a BPA call under GS00F012BA-HHSF223201810005B, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40123F19297 competed?
The extent of competition for 75F40123F19297 was full and open competition. It was set aside: Competitive 8(a).
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award